Rationale: Individuals with cystic fibrosis (CF) experience frequent acute pulmonary
exacerbations, which lead to decreased lung function and reduced quality of life. Objectives: The …

Rationale: People with cystic fibrosis (CF) experience acute worsening of respiratory
symptoms and lung function known as pulmonary exacerbations. Treatment with intravenous …

Background Males experience increased severity of illness and mortality from severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) compared with females, but the …

The stasis of mucus secretions in the lungs of cystic fibrosis (CF) patients leads to recurrent
infections and pulmonary exacerbations, resulting in decreased survival. Prior studies have …

Background Pulmonary Exacerbations (PEx) are associated with increased morbidity and
mortality in individuals with CF. PEx management practices vary widely, and optimization …

Rationale: In July 2015, the US Food and Drug Administration approved lumacaftor/ivacaftor
for use in patients with cystic fibrosis (CF). This drug targets the primary defect in the CFTR …

Background The Standardized Treatment of Pulmonary Exacerbations (STOP) program has
the intent of defining best practices in the treatment of pulmonary exacerbations (PEx) in …

Background Asthma is a heterogeneous disease, encompassing both atopic and non‐atopic
phenotypes. Diagnosis of asthma is based on the combined presence of typical symptoms …

Diffusion of the viral vectors evaluated in inhaled gene therapy clinical trials to date are
largely hindered within airway mucus, which limits their access to, and transduction of, the …

Adeno‐associated virus (AAV) vector has shown multiple clinical breakthroughs, but its
clinical implementation in inhaled gene therapy remains elusive due to difficulty in transducing …